期刊
BRAIN PATHOLOGY
卷 24, 期 3, 页码 261-269出版社
WILEY
DOI: 10.1111/bpa.12116
关键词
Alzheimer's disease; geniposide; glucagon-like peptide-1 receptor; glycogen synthase kinase-3 beta; tau hyperphosphorylation; type 2 diabetes
资金
- Shanxi Science and Technology Department [2010081062]
- Shanxi Scholarship Council of China [2007-46]
Intracerebral-ventricular (ICV) injection of streptozotocin (STZ) induces an insulin-resistant brain state that may underlie the neural pathogenesis of sporadic Alzheimer disease (AD). Our previous work showed that prior ICV treatment of glucagon-like peptide-1 (GLP-1) could prevent STZ-induced learning memory impairment and tau hyperphosphorylation in the rat brain. The Chinese herbal medicine geniposide is known to relieve symptoms of type 2 diabetes. Because geniposide is thought to act as a GLP-1 receptor agonist, we investigated the potential therapeutic effect of geniposide on STZ-induced AD model in rats. Our result showed that a single injection of geniposide (50 mu M, 10 mu L) to the lateral ventricle prevented STZ-induced spatial learning deficit by about 40% and reduced tau phosphorylation by about 30% with Morris water maze test and quantitative immunohistochemical analysis, respectively. It has been known that tau protein can be phosphorylated by glycogen synthase kinase-3 (GSK3) and STZ can increase the activity of GSK3 beta. Our result with Western blot analysis showed that central administration of geniposide resulted in an elevated expression of GSK3 beta(pS-9) but suppressed GSK3 beta(pY-216) indicating that geniposide reduced STZ-induced GSK3 beta hyperactivity. In addition, ultrastructure analysis showed that geniposide averted STZ-induced neural pathology, including paired helical filament (PHF)-like structures, accumulation of vesicles in synaptic terminal, abnormalities of endoplasmic reticulum (ER) and early stage of apoptosis. In summary, our study suggests that the water soluble and orally active monomer of Chinese herbal medicine geniposide may serve as a novel therapeutic agent for the treatment of sporadic AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据